High dose irradiation after pleurectomy/decortication or biopsy for pleural mesothelioma treatment

Parisi, Elisabetta; Romeo, Antonino; Sarnelli, Anna; Ghigi, G.; Bellia, S.R.; Neri, Elisa; Micheletti, S.; Dipalma, B.; Arpa, D.; Furini, G.; Burgio, Marco Angelo; Genestreti, Giovenzio; Gurioli, Carlo; Sanna, Stefano; Bovolato, P; Rea, Federico; Storme, Guy; Scarpi, Emanuela; Arienti, Chiara; Tesei, Anna; Polico, R.

doi:10.1016/j.canrad.2017.05.007

Cited by 11 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An important issue in our study was dosage appropriateness. We used BED 10 at the isocenter as a function of tumor size (mean tumor volume was 150 cc) [34]. The calculated mean dose to the tumor was 74 Gy.…”

Section: Discussionmentioning

confidence: 99%

Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up

et al. 2019

View full text Add to dashboard Cite

Background Concurrent chemotherapy and radiation using conventional fractionation is the standard treatment for inoperable, locally advanced non-small-cell lung cancer (NSCLC). We tested accelerated hypofractionated radiotherapy (AHR) and chemotherapy for the treatment of locally advanced NSCLC. Methods Eligible patients with locally advanced NSCLC were treated with induction chemotherapy (cisplatin and docetaxel), followed by AHR using tomotherapy and consolidation chemotherapy. The prescribed doses were 30 Gy/5 daily fractions at the reference isodose (60–70%) to the tumor, and 25 Gy/5 daily fractions to the clinically involved lymph nodes. The primary end-point was response rate (RR); the secondary end-points were acute and late side-effects, local progression-free survival (PFS), metastasis-free survival (MFS) and overall survival (OS). This trial closed before the first planned interim analysis due to poor accrual. Results From January 2009 to January 2012, 17 of the 23 enrolled patients were evaluable. Treatment yielded an overall RR of 82%. Median follow-up was 87 months (range: 6–87), local PFS was 19.8 months (95% CI 9.7 - not reached), MFS was 9.7 months (95% CI 5.8–46.0) and OS was 23 months (95% CI 8.4–48.4). 70% of patients experienced acute G4 neutropenia, 24% G4 leukopenia, 24% G3 paresthesia, 4% G3 cardiac arrythmia, 4% underwent death after chemotherapy. Late toxicity was represented by 24% dyspnea G3. Conclusions AHR combined with chemotherapy is feasible with no severe side-effects, and it appears highly acceptable by patients. Trial registration This study is registered with the EudractCT registration 2008-006525-14 . Registered on 9 December 2008.

show abstract

Section: Discussionmentioning

confidence: 99%

Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up

et al. 2019

View full text Add to dashboard Cite

show abstract

“…by de Perrot and Cho (1) and "Lung-sparing intensity-modulated radiotherapy in malignant pleural mesothelioma: palliative or potentially radical?" by Botticella and De Ruysscher (2), both addressed to our previous publication on hypofractionation and pleural mesothelioma (3). We thank the physicians for their comments and take the opportunity of responding in this Letter to the Editor.…”

mentioning

confidence: 88%

Invited letter to the editor on the editorials on “High dose irradiation after pleurectomy/decortication or biopsy for pleural mesothelioma treatment”

Parisi

Romeo

2018

J. Thorac. Dis

View full text Add to dashboard Cite

“…Auch alternative intrathorakale Maßnahmen, wie die Spülung mit erhitzter Povidon-Iod-Lösung, die Anwendung von Wasserstoffperoxid (H 2 O 2 ) oder mit Cisplatin versetzte Fibrinkleber, werden zurzeit in experimentellen und klinischen Studien analysiert [24,25]. Des Weiteren wird der Stellenwert einer zusätzlichen Radiatio in Studien untersucht und zeigte zuletzt erste positive Ergebnisse [26].…”

Section: Diskussionunclassified

Anwendung der hyperthermen intrathorakalen Chemotherapie (HITHOC) in Deutschland

et al. 2018

View full text Add to dashboard Cite

show abstract

High dose irradiation after pleurectomy/decortication or biopsy for pleural mesothelioma treatment

Cited by 11 publications

References 30 publications

Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up

Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up

Invited letter to the editor on the editorials on “High dose irradiation after pleurectomy/decortication or biopsy for pleural mesothelioma treatment”

Anwendung der hyperthermen intrathorakalen Chemotherapie (HITHOC) in Deutschland

Contact Info

Product

Resources

About